The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review (Q36940038)

17 August 2017

1 reference

title

The safety of tacrolimus ointment for the treatment of atopic dermatitis: a review (English)

1 reference

17 August 2017

0 references

1 reference

1 reference

Rustin MH

1 reference

17 August 2017

language of work or name

English

0 references

publication date

13 September 2007

1 reference

British Journal of Dermatology

17 August 2017

published in

1 reference

17 August 2017

volume

157

1 reference

17 August 2017

1 reference

17 August 2017

page(s)

861-873

1 reference

Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

FK506 inhibition of histamine release and cytokine production by mast cells and basophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Topical immunomodulatory agents and their targets in inflammatory skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

The efficacy and safety of tacrolimus ointment: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone acetate ointment in children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

0.03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: results of a randomized double-blind controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment is safe and effective in the treatment of atopic dermatitis: results in 8000 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Comparison of the efficacy and safety of 0.1% tacrolimus ointment with topical corticosteroids in adult patients with atopic dermatitis: review of randomised, double-blind clinical studies conducted in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A randomized investigator-blinded study comparing pimecrolimus cream 1% with tacrolimus ointment 0.03% in the treatment of pediatric patients with moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Malignancy after transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

The safety and efficacy of tacrolimus therapy in patients younger than 2 years with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A short-term trial of tacrolimus ointment for atopic dermatitis. European Tacrolimus Multicenter Atopic Dermatitis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A multicenter study of the pharmacokinetics of tacrolimus ointment after first and repeated application to children with atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

The role of topical calcineurin inhibitors in atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment reduces staphylococcal colonization of atopic dermatitis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment for the treatment of atopic dermatitis is not associated with an increase in cutaneous infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Pneumococcal seroconversion after vaccination for children with atopic dermatitis treated with tacrolimus ointment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment does not affect the immediate response to vaccination, the generation of immune memory, or humoral and cell-mediated immunity in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Topical calcineurin inhibitors decrease the production of UVB-induced thymine dimers from hairless mouse epidermis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Anti-tumor-promoting action of FK506, a potent immunosuppressive agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Topical application of the immunosuppressant tacrolimus accelerates carcinogenesis in mouse skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus: focusing on atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Review of the potential photo-cocarcinogenicity of topical calcineurin inhibitors: position statement of the European Dermatology Forum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Consensus statement on the safety profile of topical calcineurin inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Report of the Topical Calcineurin Inhibitor Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

The use of topical calcineurin inhibitors in dermatology: safety concerns. Report of the American Academy of Dermatology Association Task Force.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Non-melanoma skin cancer in patients with atopic dermatitis treated with topical tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

A randomized, 12-year primary-prevention trial of beta carotene supplementation for nonmelanoma skin cancer in the physician's health study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Tacrolimus ointment 0.03% shows efficacy and safety in pediatric and adult patients with mild to moderate atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Different skin thinning potential of equipotent medium-strength glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

Effects of 1-year intermittent treatment with topical tacrolimus monotherapy on skin collagen synthesis in patients with atopic dermatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2007.08177.X

10.1111/J.1365-2133.2007.08177.X

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference